A Phase 3 Study of Epaminurad vs Febuxostat for Gout

Completed Phase 3 NCT05815901

Study Description

Evaluating the Effectiveness and Safety of Two Gout Medications

Study Details

Registry ID:
NCT05815901
Conditions:
Gout
Phase:
Phase 3
Target Enrollment:
612 participants
Start Date:
Age Range:
19–75 years
Healthy Volunteers:
No

Study Locations (2 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →